ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is making headlines with the sudden announcement of the CEO’s retirement and an application delay for the company’s leading drug.
In a research report issued today, Needham analyst Alan Carr reiterated a Buy rating on Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) and reduced the price target to …
In a research report published today, Needham analyst Rajvindra Gill reiterated a Buy rating on Freescale Semiconductor Ltd (NYSE:FSL) and raised the price target to …
In a research report issued today, Needham analyst Alan Carr reiterated a Buy rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a $40 price target, after …
In a research report released today, Needham analyst Alan Carr maintained a Buy rating on Cempra (NASDAQ:CEMP) with a $42 price target, based on …
In a research report released today, Needham analyst Alan Carr maintained a Hold rating on VIVUS, Inc.(NASDAQ:VVUS), following the company’s fourth-quarter results, posting $12.
In a research report published Thursday, Needham analyst Alan Carr reiterated a Hold rating on VIVUS, Inc. (NASDAQ:VVUS), as the company is expected to announce …
In a research report released this morning, Needham analyst Alan Carr reiterated a Hold rating on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), ahead of the company’s …
In a research report sent to investors today, Needham analyst Alan Carr reiterated a Buy rating on Gilead Sciences (NASDAQ:GILD) with a price target …
In a research report published Thursday, Needham analyst Alan Carr downgraded shares of Vertex Pharmaceuticals (NASDAQ:VRTX) from Buy to Hold, following the company’s fourth-quarter financial results, which were …
